/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY...

Related Keywords

Canada , Valencia , Carabobo , Venezuela , Ohio , United States , Houston , Texas , Ohio State University , Spring House , British Columbia , Boston , Massachusetts , Toronto , Ontario , Memorial Hermann Hospital , American , Katie Shanahan , Moise Kj Jr , Katie Abouzahr , Kennethj Moise Jr , Bridget Kimmel , Kenneth Moise , Janssen Pharmaceutical Companies Of Johnson , Drug Administration , Bloomberg , Fetal Medicine Foundation World Congress , Janssen Pharmaceutical Companies , Allo Hope Foundation , European Medicines Agency , National Library Of Medicine , University Of Toronto Fetal Medicine , Janssen Research Development , Johnson , Hematology Am Soc Hematol Educ Program , Momenta Pharmaceuticals Announces Fast Track Designation , Fetal Care Center , Department Of Women Health , Exchange Commission , None Of The Janssen Pharmaceutical Companies , Companies Of Johnson , Fetal Center At Children Memorial Hermann Hospital , Comprehensive Fetal Care Center , Dell Medical School , Executive Director , Allo Hope , Vice President , Autoantibody Portfolio , Maternal Fetal Disease Area Leader , Janssen Research , Fast Track , Fetal Center , Maternal Fetal Medicine , Toronto Fetal Medicine , Mount Sinai Hospital , American Journal , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Pregnant Individuals , High Risk , Early Onset Severe Hemolytic Disease , Oral Presentation , Transfus Apher , Drug Designations , Hemolytic Diseases , Hemolytic Disease , Expert Review , The Janssen Pharmaceutical Companies Of Johnson Amp ,